search for




 

Cost Effectiveness of Insulin Glargine/Lixisenatide for Patients with Type 2 Diabetes Inadequately Controlled on Basal Insulin in South Korea
Yakhak Hoeji 2019;63(1):1-14
Published online February 28, 2019
© 2019 The Pharmaceutical Society of Korea.

Hae-Young Park*,†, Sena An*,†, Susan Park*, Dong-Ha Kim*, Hye Ok Kim**, Jeong-Mi Kwon**, and Jin-Won Kwon*,#

*College of Pharmacy and Research Institute of Pharmaceutical Sciences, Kyungpook National University **Sanofi-Aventis Korea Co., Ltd.
Correspondence to: Jin-Won Kwon, College of Pharmacy and Research Institute of Pharmaceutical Sciences, Kyungpook National University, 80 Daehak-ro Buk-gu, Daegu 41566, South Korea, Tel: +82-53-950-8580, Fax: +82-53-950-8557, E-mail: jwkwon@knu.ac.kr
Received October 29, 2018; Revised December 28, 2018; Accepted December 31, 2018.
Abstract
This study aimed to assess the cost-effectiveness of insulin glargine/lixisenatide (iGlarLixi) in comparison with premixed insulin for patients with basal insulin-uncontrolled type 2 diabetes in South Korea. The CORE Diabetes Model, a Markov model, was used with the following settings: a 30 year horizon, a payer perspective, and a 3% discount rate. Each treatment was assumed to be administered for the first 3 years, and then switched to rescue regimen. The baseline HbA1c and body mass index (BMI) were 8.6 ± 1.3%, and 24.4 ± 3.3 kg/m2, respectively. Indirect treatment comparisons showed that iGlarLixi resulted in significantly greater reduction from baselines for HbA1c and BMI compared with premixed insulin; −0.50% (95% confidence interval (CI): −0.68, −0.32) for HbA1c and −0.80 kg/m2 (95% CI: −1.29, −0.31) for BMI. In the base analysis, iGlarLixi was found to be dominant (more effective and less costly) over premixed insulin with 0.079 additional quality-adjusted life-years and lowered cost by approximately 230 USD, and the incremental cost-utility ratios from sensitivity analyses also remained dominant or below 10,000 USD. This study demonstrated that iGlarLixi was cost effective for treating patients with type 2 diabetes with poor glucose control on basal insulin in comparison with premixed insulin in South Korea.
Keywords : Cost-utility analysis, insulin glargine, glucagon-like peptide-1 receptor, diabetes mellitus


February 2019, 63 (1)
Full Text(PDF) Free

Social Network Service
Services

Cited By Articles
  • CrossRef (0)